Status:
COMPLETED
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
Lead Sponsor:
Bayer
Conditions:
Venous Thromboembolism
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.
Eligibility Criteria
Inclusion
- Male and female patients aged 18 years or above
- Patients scheduled for elective total hip replacement
Exclusion
- Planned, staged total bilateral hip replacement
- Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin
- Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin
- Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2007
Estimated Enrollment :
4541 Patients enrolled
Trial Details
Trial ID
NCT00329628
Start Date
February 1 2006
End Date
March 1 2007
Last Update
October 28 2014
Active Locations (215)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35205
2
Northport, Alabama, United States, 35476
3
Phoenix, Arizona, United States, 85023
4
Benton, Arkansas, United States, 72015